Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry

被引:57
作者
Kosovec, Juliann E. [1 ]
Egorin, Merrill J. [1 ,2 ,3 ]
Gjurich, Susanna [4 ]
Beumer, Jan H. [1 ,5 ]
机构
[1] Univ Pittsburgh, Inst Canc, Mol Therapeut Drug Discovery Program, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Div Hematol Oncol, Dept Med, Sch Med, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA
[4] Univ Pittsburgh, Inst Canc, Clin Res Serv, Pittsburgh, PA 15213 USA
[5] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15213 USA
关键词
D O I
10.1002/rcm.3362
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
5-Fluorouracil (5-FU) has long had a place in the treatment of many malignancies. 5-FU plasma concentrations have been correlated with toxicity and efficacy, and therapeutic drug monitoring has been reported to result in an improved response/toxicity balance. We report validation, according to FDA guidelines, of a hydrophilic interaction chromatography (HILIC) liquid chromatography/ tandem mass spectrometry (LC/MS/MS) assay for the sensitive, accurate and precise quantitation of 5-FU in human plasma. The assay employed an isotopically labeled 5-FU internal standard and ethyl acetate extraction. Separation was achieved with an amino column and an isocratic mobile phase of 0.1% formic acid in acetonitrile/water (97:3, v/v), followed by a wash. Detection consisted of electrospray, negative-mode ionization tandem mass spectrometry in the multiple reaction monitoring (MRM) mode. The accuracy was 96.0-102.2%, and precision was 2.1-7.5% in the concentration range of 10-10 000 ng/mL. Recovery from plasma was 46.0-72.6%, and ion suppression was 9.8-25.7%. Plasma freeze/thaw stability was 87.5-104.3%, and stability for 4h at room temperature was 98.7-100.0%. This assay is currently being used to quantitate 5-FU in human plasma samples. Copyright (c) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:224 / 230
页数:7
相关论文
共 36 条
[1]  
[Anonymous], 2001, Guidance for industry, bioanalytical method validation
[2]   THE ANALYSIS OF 5-FLUOROURACIL IN HUMAN PLASMA BY GAS-CHROMATOGRAPHY NEGATIVE-ION CHEMICAL IONIZATION MASS-SPECTROMETRY (GC-NICIMS) WITH STABLE ISOTOPE-DILUTION [J].
BATES, CD ;
WATSON, DG ;
WILLMOTT, N ;
LOGAN, H ;
GOLBERG, J .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1991, 9 (01) :19-21
[3]   Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine in mice [J].
Beumer, Jan H. ;
Eiseman, Julie L. ;
Parise, Robert A. ;
Joseph, Erin ;
Holleran, Julianne L. ;
Covey, Joseph M. ;
Egorin, Merrill J. .
CLINICAL CANCER RESEARCH, 2006, 12 (24) :7483-7491
[4]  
BEUMER JH, 2007, IN PRESS CANC CHEMOT
[5]  
Bocci G, 2000, CLIN CANCER RES, V6, P3032
[6]   Simple high-performance liquid chromatographic method for the quantitation of 5-fluorouracil in human plasma [J].
Compagnon, P ;
Thiberville, L ;
Moore, N ;
Thuillez, C ;
Lacroix, C .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 677 (02) :380-383
[7]  
DEBRUIN EA, 1983, J CHROMATOGR, V279, P603
[8]   FLAME-IONIZATION GLC ASSAY FOR FLUOROURACIL IN PLASMA OF CANCER-PATIENTS [J].
DELEENHEER, AP ;
COSYNSDUYCK, MC .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (09) :1174-1176
[9]   Rapid and simultaneous determination of capecitabine and its metabolites in mouse plasma, mouse serum, and in rabbit bile by high-performance liquid chromatography [J].
Dhananjeyan, Mugunthu R. ;
Liu, Jidong ;
Bykowski, Crystal ;
Trendel, Jill A. ;
Sarver, Jeffrey G. ;
Ando, Howard ;
Erhardt, Paul W. .
JOURNAL OF CHROMATOGRAPHY A, 2007, 1138 (1-2) :101-108
[10]  
Di Paolo A, 2005, THER DRUG MONIT, V27, P362